サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363298

子宮頸がん診断市場規模、シェア、動向分析レポート：検査タイプ別、年齢層別、最終用途別、地域別、セグメント別予測、2023年～2030年

Cervical Cancer Diagnostic Market Size, Share & Trends Analysis Report By Test Type (Pap Testing Or Cytology Testing, HPV Testing, Colposcopy, Cervical Biopsies), By Age Group, By End Use, By Region, And Segment Forecasts, 2023 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
子宮頸がん診断市場規模、シェア、動向分析レポート：検査タイプ別、年齢層別、最終用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月27日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

子宮頸がん診断市場の成長と動向：

Grand View Research, Inc.の最新調査によると、子宮頸がん診断の世界市場規模は2023年から2030年にかけてCAGR 5.7%で成長し、2030年には70億米ドルに達すると予測されています。

主な促進要因は、子宮頸がんの有病率の上昇、スクリーニング技術の進化、定期検診とスクリーニングを促進する様々なプログラムなどです。WHOが発表したデータによると、2012年には27万人以上の女性が子宮頸がんが原因で死亡しており、その大半は発展途上国の女性でした。子宮頸がんは、女性に最も多く診断されるがんのひとつです。子宮頸がんは、女性のがんの中で最も多く診断されるものひとつであり、その病因としては、複数のセックスパートナー、飲酒や喫煙、ストレスの増加といったライフスタイルの変化が挙げられます。

さらに、政府の積極的な取り組みや啓発プログラムの増加が、今後数年間の市場成長を促進すると期待されています。全米子宮頸がん連合、WHO、CDC、米国予防サービス作業部会は、中年女性の子宮頸がん早期検診の必要性を推進するために取り組んでいます。

疾患の早期介入を促進する技術的に高度な診断手順への需要が高まっています。業界各社は、正確で効率的な結果を得るための革新的な技術ソリューションの開発に注力しています。バイオマーカーの使用など、スクリーニング技術の進歩が重要性を増しています。技術開発の急増は、業界の成長をさらに促進すると予想されます。

パップテストの採用が増加しているため、子宮頸がんによる死亡者数はここ数年で大幅に減少しています。パップテストは前がん病変を早期に発見するのに役立つため、子宮頸がんの患者数を減少させる。米国がん協会は、米国における過去40年間の子宮頸がん患者数は50％以上減少したと述べています。当初、パップテスト検診は毎年実施され、不必要な処置が行われていました。しかし、現在では、米国がん協会は、21歳から29歳の女性は3年ごとにパップテストを受けることを推奨しています。

子宮頸がん診断市場レポートハイライト：

  • 2022年の市場シェアは、パップテスト部門が33.06％と過半数を占めました。このセグメントの大きなシェアは、早期診断における検査の高い効率性に起因しています。また、早期診断の影響に関する意識の高まりも、同分野の成長に寄与しました。
  • 2022年には、北米が45.74%の収益シェアで地域市場をリードしていました。米国は北米の主要市場です。子宮頸がんの罹患率の増加と、早期検診に関連する意識向上プログラムの形で政府機関により実施された取り組みが、同国の市場シェアが大きい主な要因です。
  • アジア太平洋地域は、予測期間中にCAGR 8.6％で成長し、有利な成長を示すことが期待されています。インド、中国、フィリピンなどの発展途上国の政府が、医療インフラを改善し、医療施設へのアクセスを向上させるためにさまざまな措置を講じていることが、この地域の高成長の主な要因となっています。また、発展途上国におけるがんの有病率の高さと、消費者の意識レベルの向上も成長を後押ししています。
  • この市場は現在、Becton, Dickinson and Company、F. Hoffmann-La Roche Ltd、Abbott Laboratories、OncoHealth Corp、Hologic, Inc.、QIAGEN、Quest Diagnostics, Inc.、Guided Therapeutics, Inc.などの主要参入企業によって支配されています。主な企業は、診断のための革新的なソリューションの開発に特に注力しています。例えば、F. Hoffmann-La Roche Ltd.は2014年、前がん細胞の存在を効率的に検出する自動CINtec PLUS細胞診検査を発売しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 子宮頸がん診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 業界のバリューチェーン分析
    • 償還の枠組み
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 子宮頸がん診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 主要取引と戦略的提携の分析
    • 市場参入戦略

第4章 子宮頸がん診断市場：検査タイプ別推定・動向分析

  • 子宮頸がん診断市場、検査タイプ別の重要なポイント
  • 子宮頸がん診断市場：動向と市場シェア分析、2022年および2030年
  • パップテスト
  • HPV検査
  • コルポスコピー
  • 子宮頸部生検
  • 膀胱鏡検査

第5章 子宮頸がん診断市場：年齢層別推定・動向分析

  • 子宮頸がん診断市場、年齢層別の重要なポイント
  • 子宮頸がん診断市場：動向と市場シェア分析、2022年および2030年
  • 20～40歳
  • 40歳以上

第6章 子宮頸がん診断市場：最終用途別推定・動向分析

  • 子宮頸がん診断市場、最終用途別の重要なポイント
  • 子宮頸がん診断市場：動向と市場シェア分析、2022年および2030年
  • 病院
  • ラボ
  • 診断センター

第7章 子宮頸がん診断市場：地域別推定・動向分析

  • 地域別の展望
  • 地域別の子宮頸がん診断市場：マーケットプレースにおける重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • Abbott Laboratories
    • Ouigan NV
    • Thermo Fisher Scientific Inc
    • Dickinson and Company
    • Hologic Inc
    • CooperSurgical Inc
    • Siemens Healthineers
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 3 North America cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 4 North America cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 5 North America cervical cancer diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 7 U.S. cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 8 U.S. cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 10 Canada cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 11 Canada cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Europe cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 14 Europe cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe cervical cancer diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 17 Germany cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 18 Germany cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 20 UK cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 21 UK cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 23 France cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 24 France cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 26 Italy cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 27 Italy cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Spain cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 30 Spain cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Sweden cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 32 Sweden cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 33 Sweden cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Norway cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 35 Norway cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 36 Norway cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Denmark cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 38 Denmark cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 39 Denmark cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific cervical cancer diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 44 China cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 45 China cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 46 China cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Japan cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 48 Japan cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 49 Japan cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 51 India cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 52 India cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Thailand cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Thailand cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 55 Thailand cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 56 South Korea cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 57 South Korea cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 58 South Korea cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Latin America cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 60 Latin America cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 61 Latin America cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America cervical cancer diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 63 Brazil cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 64 Brazil cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 65 Brazil cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Mexico cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 67 Mexico cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 68 Mexico cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Argentina cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 70 Argentina cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 71 Argentina cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Middle East and Africa cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 73 Middle East and Africa cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 74 Middle East and Africa cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa cervical cancer diagnostic market, by region, 2018 - 2030 (USD Million)
  • Table 76 South Africa cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 77 South Africa cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 78 South Africa cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 82 UAE cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 83 UAE cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 84 UAE cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Kuwait cervical cancer diagnostic market, by test type, 2018 - 2030 (USD Million)
  • Table 86 Kuwait cervical cancer diagnostic market, by age group, 2018 - 2030 (USD Million)
  • Table 87 Kuwait cervical cancer diagnostic market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Cervical cancer diagnostic: Market outlook
  • Fig. 9 Cervical cancer diagnostic: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Cervical cancer diagnostic market driver impact
  • Fig. 15 Cervical cancer diagnostic market restraint impact
  • Fig. 16 Cervical cancer diagnostic market strategic initiatives analysis
  • Fig. 17 Cervical cancer diagnostic market: Test Type movement analysis
  • Fig. 18 Cervical cancer diagnostic market: type outlook and key takeaways
  • Fig. 19 Pap testing market estimates and forecasts, 2018 - 2030
  • Fig. 20 HPV testing market estimates and forecasts, 2018 - 2030
  • Fig. 21 Colposcopy market estimates and forecasts, 2018 - 2030
  • Fig. 22 Cervical biopsies market estimates and forecasts, 2018 - 2030
  • Fig. 23 Cytoscopy market estimates and forecasts, 2018 - 2030
  • Fig. 24 Cervical cancer diagnostic market: Age-group movement analysis
  • Fig. 25 Cervical cancer diagnostic market: age-group outlook and key takeaways
  • Fig. 26 20-40 years market estimates and forecasts, 2018 - 2030
  • Fig. 27 Above 40 years market estimates and forecasts, 2018 - 2030
  • Fig. 28 Cervical cancer diagnostic market: End use movement analysis
  • Fig. 29 Cervical cancer diagnostic market: end use outlook and key takeaways
  • Fig. 30 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 31 Laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 32 Diagnostic centers management market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global Cervical cancer diagnostic market: Regional movement analysis
  • Fig. 34 Global Cervical cancer diagnostic market: regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 39 UK market estimates and forecasts, 2018 - 2030
  • Fig. 40 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 41 France market estimates and forecasts, 2018 - 2030
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 43 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 44 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 45 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 48 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 49 China market estimates and forecasts, 2018 - 2030
  • Fig. 50 India market estimates and forecasts, 2018 - 2030
  • Fig. 51 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 52 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 53 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 54 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 55 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 56 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 57 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030
  • Fig. 59 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 60 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 61 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-1-68038-127-6

Cervical Cancer Diagnostic Market Growth & Trends:

The global cervical cancer diagnostic market size is expected to reach USD 7.0 billion by 2030, growing at a CAGR of 5.7% from 2023 to 2030, according to a new study conducted by Grand View Research, Inc.. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

There is an increasing demand for technologically advanced diagnostic procedures that facilitate the early intervention of the disease. The industry players are focused on developing innovative technological solutions for accurate and efficient results. Advancement in screening techniques, such as use of biomarkers, is gaining importance. The upsurge in technological developments is anticipated to further drive industry growth.

On account of increasing adoption of Pap test, the number of deaths due to cervical cancer has declined significantly in past few years. It helps detect precancerous lesions at an early state and, thus, reduces the number of cervical cancer cases. The American Cancer Society stated that the cervical cancer cases in last 40 years in the U.S. have declined by more than 50%. Initially, the Pap test screening was carried out every year which lead to further unnecessary procedures. However, the American Cancer Society now recommends that women in the age group of 21 to 29 should undergo Pap test every 3 years.

Cervical Cancer Diagnostic Market Report Highlights:

  • In 2022, the Pap testing segment held majority of the market share of 33.06%. The segment's large share can be attributed to the high efficiency of the tests in early diagnosis. Also, the increasing awareness about the impact of early diagnosis contributed to its growth.
  • In 2022, North America was the leading regional market with a revenue share of 45.74%. The U.S. is a key market in North America. Growing incidence of cervical cancer coupled with initiatives undertaken by government agencies in the form of awareness programs pertaining to the early screening of the disease are key factors for the country's large market share.
  • Asia Pacific is expected to witness lucrative growth over the forecast period growing at a CAGR of 8.6%. The various steps undertaken by governments of developing countries such as India, China, Philippines, and other in order to improve healthcare infrastructure and to improve access to healthcare facilities are amongst key factors attributing to region's high growth. Also, high prevalence of cancer in developing nations and increasing consumer awareness levels drive the growth
  • This market is presently dominated by a few key participants such as Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Abbott Laboratories, OncoHealth Corp, Hologic, Inc., QIAGEN, Quest Diagnostics, Inc and Guided Therapeutics, Inc. The key players focus specially on developing innovative solutions for diagnosis. For instance, F. Hoffmann-La Roche Ltd., in 2014, launched automated CINtec PLUS cytology test that efficiently detects the presence of precancerous cells.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test Type
    • 1.1.2. Age group
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
    • 2.2.2. Age group outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cervical Cancer Diagnostic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. The increasing demand for cervical cancer screening tools
      • 3.4.1.2. Increase in cervical cancer cases across the globe
      • 3.4.1.3. Technological advancements
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. Limited number of approved products
      • 3.4.2.2. Complications/risks associated with microneedles
  • 3.5. Cervical Cancer Diagnostic Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape
    • 3.5.3. Major Deals & Strategic Alliances Analysis
    • 3.5.4. Market Entry Strategies

Chapter 4. Cervical Cancer Diagnostic Market: Test Type Estimates & Trend Analysis

  • 4.1. Cervical Cancer Diagnostic Market, By Test Type Key Takeaways
  • 4.2. Cervical Cancer Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Pap Testing
    • 4.3.1. Pap testing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. HPV Testing
    • 4.4.1. HPV testing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Colposcopy
    • 4.5.1. Colposcopy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Cervical Biopsies
    • 4.6.1. Cervical biopsies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Cystoscopy
    • 4.7.1. Cystoscopy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cervical Cancer Diagnostic market: Age group Estimates & Trend Analysis

  • 5.1. Cervical Cancer Diagnostic Market, By Age group Key Takeaways
  • 5.2. Cervical Cancer Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. 20-40 years
    • 5.3.1. 20-40 years market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Above 40 years
    • 5.4.1. Above 40 years market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cervical Cancer Diagnostic market: End Use Estimates & Trend Analysis

  • 6.1. Cervical Cancer Diagnostic Market, By End Use Key Takeaways
  • 6.2. Cervical Cancer Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Laboratories
    • 6.4.1. Laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Diagnostic Centers
    • 6.5.1. Diagnostic centers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cervical Cancer Diagnostic Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Cervical Cancer Diagnostic Market by Region: Key Marketplace Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
    • 8.2.1. Abbott Laboratories
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Ouigan NV
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Thermo Fisher Scientific Inc
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Dickinson and Company
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Hologic Inc
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. CooperSurgical Inc
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Siemens Healthineers
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives